The aim of this review is to discuss current options and clinical efficacy of monoclonal antibodies targeting PCSK9 or ANGPTL3 in FH patients according to the genetic mutations underlying the disease. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.